Samsung Biologics Plans Record 3 Trillion Won Share Sale for Swiss Deal
▲ AI PRISM* Personalized Economic Briefing * Editor’s note: AI PRISM (Personalized Report & Insight Summarizing Media) is…
Samsung Biologics Acquires Swiss CDMO for approximately $1.8 Billion, Making a Major Push into the Obesity Drug Market — BigGo Finance
Samsung Biologics (207940) is investing approximately 2.7 trillion won (approximately $1.8 billion) to acquire PolyPeptide Group, a global…
Samsung Biologics Acquires Swiss PolyPeptide Group for approximately $1.8 Billion, Targeting Obesity Drug Market — BigGo Finance
Samsung Biologics is making a blockbuster acquisition of PolyPeptide Group AG, a Swiss peptide contract development and manufacturing…
Samsung Biologics Bets $1.8 Billion on ‘K-Obesity Drug’ Play with Swiss PolyPeptide Acquisition — BigGo Finance
Samsung Biologics has thrown its hat into the rapidly growing global obesity treatment market, committing 2.7 trillion won…
Samsung Biologics Acquires Swiss Peptide CDMO PolyPeptide Group for approximately $1.8 Billion — BigGo Finance
Samsung Biologics (207940) has placed a major bet on capturing the global peptide contract development and manufacturing organization…
Switzerland: Samsung Biologics to acquire PolyPeptide for US$1.8bn
Listed South Korean CDMO, Samsung Biologics, is acquiring all shares in SIX-listed PolyPeptide, a specialised CDMO for peptide-based…
Samsung Biologics to Acquire Swiss Peptide CDMO for approximately $1.8 Billion, Targeting Obesity Drug Market — BigGo Finance
Samsung Biologics (207940.KS) announced on the 20th that it will acquire PolyPeptide Group, a global peptide contract development…